Mainstay Medical announces completion of financing transactions
• Funds to be used to support PMA process for ReActiv8® in US and to further European commercial validation efforts
• Gross proceeds, together with savings from previously-announced debt restructuring, provides approximately $28 million in cash runway extension
Dublin, Ireland: 29 July 2019 – Mainstay Medical International plc (Euronext Paris: MSTY.PA and Euronext Growth of Euronext Dublin: MSTY.IE), a medical device company focused on bringing to market ReActiv8®, an implantable neurostimulation system to treat disabling Chronic Low Back Pain, announces today that it has completed financing transactions to raise gross proceeds of € 16.9 million (US$ 18.9 million).
More information on Mainstay’s website.